The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - REMD Biotherapeutics
Leadership - REMD Biotherapeutics
Stock and Other Ownership Interests - REMD Biotherapeutics
Consulting or Advisory Role - ARMO BioSciences
A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
 
Manish A. Shah
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Jean-Philippe Metges
Consulting or Advisory Role - Bayer; Lilly; MSD
Research Funding - Array BioPharma (Inst); Gilead Sciences (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD; Roche
 
David Cunningham
Research Funding - 4SC (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Sanofi (Inst)
 
Kai-Keen Shiu
Honoraria - Merck Serono; Roche; SERVIER
Consulting or Advisory Role - Merck Serono; Roche; SERVIER
Research Funding - MSD (Inst); Roche (Inst)
 
Lucjan Wyrwicz
No Relationships to Disclose
 
Dung Thai
No Relationships to Disclose
 
Carrie Brachmann
Employment - BeiGene (I); Gilead Sciences; OncoMed (I)
Stock and Other Ownership Interests - BeiGene (I); Celgene; Gilead Sciences; OncoMed (I); Roche (I); Vertex
 
Pankaj Bhargava
Employment - Gilead Sciences
Leadership - Tioma Therapeutics
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Dicerna
Patents, Royalties, Other Intellectual Property - AVEO; Sanofi
 
Daniel V.T. Catenacci
Honoraria - Amgen; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Genmab; Gritstone Bio; Guardant Health; Lilly; Merck; NantWorks; OncoPlex Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Guardant Health
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech